BT7480

Phase 2Small molecule

BBicycleTx Limited

BT7480 is one of 80 small molecule programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorNot yet recruiting

Advanced MalignanciesActive, not recruiting

Solid TumorPhase 2

Not yet recruiting

Advanced MalignanciesPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

DATROWAY

Daiichi Sankyo

Preclinical

1 2

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

BT7480

BBicycleTx Limited

Phase 2

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Carboplatin AUC-5

Merck & Co.

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Active, not recruiting

Advanced Malignancies

NCT05163041

Q2 2030

Phase 2Not yet recruiting

Solid Tumor

NCT07681674

Clinical

Trials by Indication[1]

Advanced Malignancies1 trial

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Active, not recruiting·BBicycleTx Limited·Phase 1/2·NCT05163041·200 enrolled

Solid Tumor1 trial

Bicycle Continued Access Protocol (BiCAP) for Participants Receiving a Bicycle Investigational Product on a BicycleTx Limited-Sponsored Study

Not yet recruiting·BBicycleTx Limited·Phase 2·NCT07681674·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BT7480. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BT7480 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BT7480. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BicycleTx Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBicycleTx Limited

BT7480

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2030

Trials by Indication[1]

Advanced Malignancies1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News